Dinutuximab
| Monoclonal antibody | |
|---|---|
| Source | Chimeric (mouse/human) |
| Target | GD2 |
| Clinical data | |
| Trade names | Unituxin |
| |
| Identifiers | |
| 1363687-32-4 | |
| Chemical data | |
Dinutuximab (tradename Unituxin) is a drug developed by United Therapeutics for the treatment of high-risk neuroblastoma in pediatric patients. It was approved for use by the United States Food and Drug Administration for use on March 10, 2015.[1]
References
- ↑ "FDA approves first therapy for high-risk neuroblastoma". http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm437460.htm''.